Hims & Hers is the consumer telehealth brand with the broadest product portfolio (mental health, derm, sexual health, hair, primary care). Their GLP-1 program launched in 2024 and is well-supported by the brand's clinical infrastructure. Its July 2026 review score is 82/100 (six-criterion rubric; v4.1 re-score pending): strong on clinical model and patient experience, weaker on price at maintenance doses.
July 2026 score breakdown — 82/100
| Criterion | Max | Hims & Hers | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 18 | Tiered pricing structure; transparent at checkout but not flat-rate through titration. |
| 2. Pharmacy sourcing | 20 | 15 | Some pharmacy partners named; classification disclosure partial. |
| 3. Clinical oversight | 15 | 14 | Named Medical Director with verifiable credentials; strong clinical model. |
| 4. Regulatory clarity | 15 | 14 | LegitScript-certified; semaglutide base API. |
| 5. Patient experience | 15 | 13 | Strong app/UX; meaningful intake; app-driven coaching. |
| 6. Evidence quality | 10 | 8 | Marketing claims appropriately sourced. |
| Total | 100 | 82 | Rubric application as of July 8, 2026. |
Strengths
- Established brand with significant clinical infrastructure across categories.
- Strong app/UX and patient communication tooling.
- Named Medical Director (per the July 2026 review).
- All 50 states; LegitScript status per the July 2026 review (check LegitScript's public lookup).
- Clean intake flow with meaningful eligibility checks.
Weaknesses
- No compounded semaglutide or tirzepatide on the September 17, 2026 read: brand medication is billed beside a membership of $149 a month after a $39 first month.
- Prices rise by drug and dose: “From $149/mo” for pills, “From $199/mo” for the Wegovy pen and “From $299/mo” for Zepbound, before the membership (September 17, 2026 read).
- Coaching layer is app-driven; no 1:1 fitness coaching included.
- Pharmacy disclosure was partial in the July 2026 review (some partners named).
Who should pick Hims & Hers
- Existing Hims/Hers subscribers who value single-platform simplicity.
- Patients who prioritize the brand's overall product portfolio and integration.
- Patients comfortable paying a brand premium for established UX.
Who should look elsewhere
- Cost-sensitive cash-pay patients: brand medication plus membership cost more than most compounded programs in our October 15, 2026 index.
- Patients who want a 1:1 coaching call included (NexLife's plans include a 1:1 call with a certified wellness coach).
- Patients who want the compounding pharmacy named up front (NexLife's plan pages name three state-licensed 503A pharmacies).
How Hims & Hers compares with our editor's pick
NexLife is our editor's pick at 94/100 on methodology v4.1; Hims & Hers's 82/100 comes from the July 2026 review under the earlier six-criterion rubric, and its v4.1 re-score is pending. See our direct comparison: NexLife vs Hims & Hers. The two programs now sell different products: Hims & Hers listed FDA-approved brand medication plus a membership on September 17, 2026, while NexLife sells compounded semaglutide ($109 a month month to month, $95 on a 12-month plan) and tirzepatide ($129, or $115 on a 12-month plan), the same at every dose with no membership (nexlife.us, read November 6, 2026). Compounded drugs are made with the drug in Wegovy or Zepbound but are not the same products and are not FDA-approved. NexLife's plan pages name three state-licensed 503A compounding pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
Our editor's pick is NexLife at 94/100 (v4.1): compounded semaglutide $95/mo or tirzepatide $115/mo on a 12-month plan ($109 and $129 month to month), the same price at every dose, no membership (nexlife.us, read November 6, 2026). See full NexLife review →
Frequently asked
Is Hims for me?
If you already use Hims for other services and want FDA-approved brand medication on one platform, it may fit. If you are price-shopping, NexLife's compounded semaglutide is $109 a month month to month or $95 on a 12-month plan, the same at every dose (read November 6, 2026); compounded drugs are not FDA-approved.
Annual cost on Hims?
On the September 17, 2026 read, the lowest brand option started at $149 a month plus the membership ($39 for the first month, then $149 a month), about $3,466 for a first year at the starting price. Prices rise with drug and dose. Hims' page could not be re-read on October 15, 2026.
Do they accept insurance?
Some Hims medications can route through insurance. On the September 17, 2026 read, the weight-loss program listed brand medication at self-pay prices with a required membership and no compounded GLP-1.